ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Roflumilast

Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.

Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 30, 201161 company-led studies, 3 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca340 open or runningphase 4since Mar 30, 2011Jun 9, 2003none ahead
Arcutis Biotherapeuticsits history only181 open or runningphase 3since Dec 23, 2019Dec 29, 2017Apr 27, 2028phase 3 · NCT07916480
Huadong Medicineits history only31 open or runningphase 3since Sep 30, 2024Sep 30, 2024Jun 30, 2027phase 3 · NCT07683806
FLUIDDA nvits history only20 open or runningphase 4since Nov 21, 2011Nov 21, 2011none ahead
Integrative Skin Science and Researchits history only11 open or runningphase 4since Apr 23, 2026Apr 23, 2026Aug 2027phase 4 · NCT07560618
Padagisits history only10 open or runningphase 3since Feb 28, 2023Feb 28, 2023none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 2since Jan 25, 2016Jan 25, 2016none ahead
Takedaits history only10 open or runningphase 1since Mar 4, 2014Mar 4, 2014none ahead

Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Jun 9, 2003.

  1. Jun 8, 2010Phase 2 study in Diabetes Mellitus, Type 2NCT01140542 · 487 enrolled
  2. Mar 3, 2011Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT01313494 · 626 enrolled · China, Hong Kong, Singapore
  3. Mar 30, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01329029 · 1,945 enrolled · Australia, Austria, Belgium and more
  4. May 16, 2011Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT01354782 · 32 enrolled · China
  5. May 30, 2011Phase 2 study in Allergic AsthmaNCT01365533 · 48 enrolled · Canada
  6. Sep 28, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01443845 · 2,354 enrolled · United States, Argentina, Canada and more
  7. Oct 31, 2011Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT01473758 · 81 enrolled · United Kingdom
  8. Dec 21, 2011Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT01509677 · 158 enrolled · Denmark, Germany, Poland and more
  9. Aug 10, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01664624 · 40 enrolled · United States
  10. Oct 2, 2012Phase 2 study in Nonalcoholic SteatohapatitisNCT01703260 · 20 enrolled · United States
  11. Jan 8, 2013Phase 2 study in AsthmaNCT01765192 · 64 enrolled · Germany, Hungary, South Africa
  12. May 14, 2013Phase 2 study in Dermatitis, AtopicNCT01856764 · 40 enrolled · Germany
  13. Jan 29, 2014Phase 1 study in Memory DisordersNCT02051335 · 27 enrolled · United Kingdom
  14. May 2, 2014Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT02165826 · 1,323 enrolled · Slovakia

TargetBeta

“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 5 targets

ProgramCompanyFurthest phaseStudies
ensifentrineruleMerckphase 317

Studies

All 34 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02165826Pulmonary Disease, Chronic Obstructive · Slovakia3CompletedSep 1, 20151,323
NCT02051335Memory Disorders · United Kingdom1CompletedMay 201427
NCT01856764Dermatitis, Atopic · Germany2CompletedMar 201440
NCT01765192Asthma · Germany, Hungary, South Africa2CompletedOct 201364
NCT01703260Nonalcoholic Steatohapatitis · United States2TerminatedSep 201420
NCT01664624Diabetes Mellitus, Type 2 · United States1CompletedNov 201240
NCT01509677Pulmonary Disease, Chronic Obstructive · Denmark, Germany, Poland and more3CompletedFeb 1, 2016158
NCT01473758Pulmonary Disease, Chronic Obstructive · United Kingdom2TerminatedMar 201481
NCT01443845Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more4CompletedNov 30, 20152,354
NCT01365533Allergic Asthma · Canada2CompletedJul 200548
NCT01354782Pulmonary Disease, Chronic Obstructive · China1CompletedJun 201132
NCT01329029Pulmonary Disease, Chronic Obstructive · Australia, Austria, Belgium and more4CompletedMar 20141,945
NCT01313494Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Singapore3CompletedMay 2012626
NCT01140542Diabetes Mellitus, Type 22CompletedNov 2007487
NCT00940329Healthy · Germany1CompletedJul 200427
NCT00746434Plaque Psoriasis2WithdrawnJun 20090
NCT00746382Dermatitis2WithdrawnJun 20090
NCT00430729Pulmonary Disease, Chronic Obstructive · Australia, Austria, Canada and more3Completed1,100
NCT00424268Pulmonary Disease, Chronic Obstructive · Austria, France, Germany and more3CompletedJan 2008743
NCT00313209Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Canada and more3CompletedJul 2007933
NCT00297115Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more3CompletedApr 20081,568
NCT00297102Pulmonary Disease, Chronic Obstructive · United States, Australia, Austria and more3CompletedJul 20081,523
NCT00246935Pulmonary Disease, Chronic Obstructive · Japan3CompletedJan 2007150
NCT00246922Asthma · Japan3CompletedJan 1, 2007150
NCT00242320Pulmonary Disease, Chronic Obstructive · Hong Kong, Korea, Republic of, Malaysia and more3CompletedMay 2007551
NCT00242307Asthma · Japan3CompletedSep 1, 2006450
NCT00242294Pulmonary Disease, Chronic Obstructive · Japan3CompletedSep 2006570
NCT00163527Asthma · United States, Austria, Croatia and more3CompletedNov 20052,054
NCT00163475Asthma · Australia, Belgium, France and more3CompletedAug 2005511
NCT00108823Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more3Completed550
NCT00076089Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more3CompletedDec 20051,100
NCT00076076Asthma · United States, Russian Federation, Ukraine3Completed822
NCT00073177Asthma · United States, Argentina, Colombia and more3Completed819
NCT00062582Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more3Completed1,000

How it is read

Names in the registry

  • “Roflumilast”, 37 entries
  • “Roflumilast Cream 0.15%”, 5 entries
  • “Roflumilast Cream 0.3%”, 3 entries
  • “ARQ-151 cream 0.05%”, 2 entries
  • “Roflumilast Foam 0.3%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.